HC Wainwright Analysts Lower Earnings Estimates for DFTX

Definium Therapeutics, Inc. (NASDAQ:DFTX) – Research analysts at HC Wainwright dropped their Q1 2026 EPS estimates for Definium Therapeutics in a research note issued to investors on Monday, March 2nd. HC Wainwright analyst P. Trucchio now anticipates that the company will post earnings of ($0.46) per share for the quarter, down from their prior forecast of ($0.38). HC Wainwright currently has a “Buy” rating and a $70.00 price target on the stock. The consensus estimate for Definium Therapeutics’ current full-year earnings is ($1.35) per share. HC Wainwright also issued estimates for Definium Therapeutics’ Q2 2026 earnings at ($0.46) EPS, Q3 2026 earnings at ($0.46) EPS, Q4 2026 earnings at ($0.46) EPS, FY2026 earnings at ($1.83) EPS, FY2027 earnings at ($1.52) EPS, FY2028 earnings at $0.72 EPS, FY2029 earnings at $3.24 EPS and FY2030 earnings at $5.32 EPS.

Other equities research analysts have also recently issued research reports about the company. JonesTrading initiated coverage on Definium Therapeutics in a report on Tuesday, December 23rd. They set a “buy” rating and a $61.00 target price on the stock. Jefferies Financial Group began coverage on shares of Definium Therapeutics in a report on Thursday, January 29th. They set a “buy” rating and a $30.00 target price for the company. Canaccord Genuity Group boosted their target price on Definium Therapeutics from $16.00 to $25.00 and gave the stock a “buy” rating in a research report on Friday, November 7th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Definium Therapeutics in a research report on Monday, February 2nd. Finally, Robert W. Baird set a $37.00 price objective on Definium Therapeutics in a report on Thursday, January 29th. Two equities research analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus target price of $35.70.

Definium Therapeutics Stock Up 0.4%

DFTX stock opened at $17.76 on Thursday. The firm’s 50-day moving average is $15.90 and its two-hundred day moving average is $12.99. The company has a market capitalization of $1.75 billion, a price-to-earnings ratio of -8.34 and a beta of 2.56. Definium Therapeutics has a 52 week low of $4.70 and a 52 week high of $18.70. The company has a current ratio of 6.29, a quick ratio of 6.29 and a debt-to-equity ratio of 0.12.

Insider Activity at Definium Therapeutics

In other news, CEO Robert Barrow sold 25,791 shares of the firm’s stock in a transaction dated Friday, December 26th. The stock was sold at an average price of $13.15, for a total transaction of $339,151.65. Following the completion of the sale, the chief executive officer directly owned 778,477 shares of the company’s stock, valued at $10,236,972.55. This trade represents a 3.21% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Mark Sullivan sold 11,276 shares of the business’s stock in a transaction that occurred on Friday, December 26th. The stock was sold at an average price of $13.15, for a total transaction of $148,279.40. Following the completion of the sale, the insider directly owned 282,576 shares of the company’s stock, valued at $3,715,874.40. This represents a 3.84% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders sold 42,667 shares of company stock valued at $561,071. Insiders own 2.26% of the company’s stock.

Hedge Funds Weigh In On Definium Therapeutics

Institutional investors have recently bought and sold shares of the stock. CenterBook Partners LP bought a new position in shares of Definium Therapeutics during the 3rd quarter worth about $1,880,000. Marshall Wace LLP grew its position in Definium Therapeutics by 31.9% during the second quarter. Marshall Wace LLP now owns 3,421,224 shares of the company’s stock worth $22,204,000 after buying an additional 828,067 shares in the last quarter. Geode Capital Management LLC increased its stake in Definium Therapeutics by 4.0% during the second quarter. Geode Capital Management LLC now owns 1,733,454 shares of the company’s stock valued at $11,252,000 after acquiring an additional 66,663 shares during the period. Persistent Asset Partners Ltd acquired a new position in Definium Therapeutics in the 2nd quarter valued at approximately $238,000. Finally, Stempoint Capital LP bought a new stake in shares of Definium Therapeutics in the 2nd quarter worth approximately $590,000. 27.91% of the stock is currently owned by institutional investors.

Key Stories Impacting Definium Therapeutics

Here are the key news stories impacting Definium Therapeutics this week:

• Positive Sentiment: HC Wainwright retained a “Buy” rating and a $70 price target and materially raised long‑range earnings power (FY2028–FY2030 upgrades, including FY2029 to $3.24 and FY2030 to $5.32), supporting a bullish, multi‑year thesis for DFTX. HC Wainwright Forecasts Strong Price Appreciation for Definium Therapeutics (NASDAQ:DFTX) Stock
• Neutral Sentiment: Reported short‑interest figures for early March were effectively zero/invalid (0 shares and NaN), so there is no clear short‑squeeze pressure or bearish positioning signal to interpret from that data.
• Negative Sentiment: HC Wainwright trimmed near‑term EPS forecasts across Q1–Q4 2026 (each to ($0.46) from ($0.38)) and lowered FY2026 to ($1.83) and FY2027 to ($1.52), indicating weaker near‑term profitability than previously expected — a potential headwind if guidance or operational updates confirm the slower short‑term trajectory.

Definium Therapeutics Company Profile

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.